Top

Published in:

Open Access 01-01-2022 | Sarcopenia | Review Article

Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment

Authors: Varvara Chatzipetrou, Marie-Josée Bégin, Mélany Hars, Andrea Trombetti

Published in: Calcified Tissue International | Issue 1/2022

Abstract

Sarcopenia, a condition characterized by loss of skeletal muscle mass and function, has important clinical ramifications. We aimed to map the existing literature about prevalence, risk factors, associated adverse outcomes, and treatment of sarcopenia in individuals with chronic kidney disease (CKD). A scoping review of the literature was conducted to identify relevant articles published from databases’ inception to September 2019. Individuals with CKD, regardless of their disease stage and their comorbidities, were included. Only studies with sarcopenia diagnosed using both muscle mass and function, based on published consensus definitions, were included. For studies on treatment, only randomized controlled trials with at least one sarcopenia parameter as an outcome were included. Our search yielded 1318 articles, of which 60 from were eligible for this review. The prevalence of sarcopenia ranged from 4 to 42% according to the definition used, population studied, and the disease stage. Several risk factors for sarcopenia were identified including age, male gender, low BMI, malnutrition, and high inflammatory status. Sarcopenia was found to be associated with several adverse outcomes, including disabilities, hospitalizations, and mortality. In CKD subjects, several therapeutic interventions have been assessed in randomized controlled trial with a muscle mass, strength, or function endpoint, however, studies focusing on sarcopenic CKD individuals are lacking. The key interventions in the prevention and treatment of sarcopenia in CKD seem to be aerobic and resistance exercises along with nutritional interventions. Whether these interventions are effective to treat sarcopenia and prevent clinical consequences in this population remains to be fully determined.

Available only for authorised users

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11(7):e0158765PubMedPubMedCentral

Ethgen O, Beaudart C, Buckinx F, Bruyere O, Reginster JY (2017) The future prevalence of Sarcopenia in Europe: a claim for public health action. Calcif Tissue Int 100(3):229–234PubMed

Cruz-Jentoft AJ et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423PubMedPubMedCentral

Cruz-Jentoft AJ et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31PubMed

Studenski SA et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 69(5):547–558PubMedPubMedCentral

Dam TT et al (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci 69(5):584–590PubMedPubMedCentral

Fielding RA et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12(4):249–256PubMed

Newman AB et al (2003) Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 51(11):1602–1609PubMed

Chen LK et al (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15(2):95–101PubMed

10.

Moon SJ, Kim TH, Yoon SY, Chung JH, Hwang HJ (2015) Relationship between stage of chronic kidney disease and Sarcopenia in Korean aged 40 years and older using the Korea National Health and Nutrition Examination Surveys (KNHANES IV-2, 3, and V-1, 2), 2008-2011. PLoS ONE 10(6):e0130740PubMedPubMedCentral

11.

Fried LF et al (2007) Kidney function as a predictor of loss of lean mass in older adults: health, aging and body composition study. J Am Geriatr Soc 55(10):1578–1584PubMed

12.

Kim H et al (2015) Incidence and predictors of sarcopenia onset in community-dwelling elderly Japanese women: 4-year follow-up study. J Am Med Dir Assoc 16(1):85 e1-85 e8

13.

Liu CK, Lyass A, Massaro JM, D’Agostino RB Sr, Fox CS, Murabito JM (2014) Chronic kidney disease defined by cystatin C predicts mobility disability and changes in gait speed: the Framingham Offspring Study. J Gerontol A Biol Sci Med Sci 69(3):301–307PubMed

14.

Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O (2017) Health outcomes of Sarcopenia: a systematic review and meta-analysis. PLoS ONE 12(1):e0169548PubMedPubMedCentral

15.

Zhao Y, Zhang Y, Hao Q, Ge M, Dong B (2019) Sarcopenia and hospital-related outcomes in the old people: a systematic review and meta-analysis. Aging Clin Exp Res 31(1):5–14PubMed

16.

Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM, Maier AB (2019) Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 10(3):485–500PubMedPubMedCentral

17.

da Silva Alexandre T, de Oliveira Duarte YA, Ferreira Santos JL, Wong R, Lebrao ML (2014) Sarcopenia according to the european working group on sarcopenia in older people (EWGSOP) versus Dynapenia as a risk factor for disability in the elderly. J Nutr Health Aging 18(5):547–553PubMed

18.

Landi F et al (2013) Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 42(2):203–209PubMed

19.

Tricco AC et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467–473PubMed

20.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6(7):e1000097PubMedPubMedCentral

21.

Aly SH, Tawfik HM, Bichari WA, El-Sadany MA, El Banouby MH (2019) Sarcopenia and risk of falls in patients with chronic kidney disease, a meet of three geriatric giants. Egypt J Geriatr Gerontol 6(1):1–5

22.

Ishikawa S et al (2018) Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PLoS ONE 13(2):e0192990PubMedPubMedCentral

23.

Pereira RA et al (2015) Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dial Transplant 30(10):1718–1725PubMed

24.

Souza VA et al (2017) Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors. PLoS ONE 12(4):e0176230PubMedPubMedCentral

25.

Vettoretti S, Caldiroli L, Armelloni S, Ferrari C, Cesari M, Messa P (2019) Sarcopenia is associated with malnutrition but not with systemic inflammation in older persons with advanced CKD. Nutrients 11(6):1378PubMedCentral

26.

Zhou Y, Hellberg M, Svensson P, Hoglund P, Clyne N (2018) Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3–5. Nephrol Dial Transplant 33(2):342–348PubMed

27.

Abro A, Delicata LA, Vongsanim S, Davenport A (2018) Differences in the prevalence of sarcopenia in peritoneal dialysis patients using hand grip strength and appendicular lean mass: depends upon guideline definitions. Eur J Clin Nutr 72(7):993–999PubMed

28.

As’habi A, Najafi I, Tabibi H, Hedayati M (2018) Prevalence of Sarcopenia and Dynapenia and their determinants in Iranian peritoneal dialysis patients. Iran J Kidney Dis 12(1):53–60PubMed

29.

Bataille S, Serveaux M, Carreno E, Pedinielli N, Darmon P, Robert A (2017) The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients. Clin Nutr 36(6):1654–1660PubMed

30.

da Silva MZC, Vogt BP, Reis N, Caramori JCT (2019) Update of the European consensus on sarcopenia: what has changed in diagnosis and prevalence in peritoneal dialysis? Eur J Clin Nutr 73:1209–1211PubMed

31.

Giglio J, Kamimura MA, Lamarca F, Rodrigues J, Santin F, Avesani CM (2018) Association of Sarcopenia with nutritional parameters, quality of life, hospitalization, and mortality rates of elderly patients on hemodialysis. J Ren Nutr 28(3):197–207PubMed

32.

Hotta C et al (2015) Relation of physical function and physical activity to sarcopenia in hemodialysis patients: a preliminary study. Int J Cardiol 191:198–200PubMed

33.

Isoyama N et al (2014) Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 9(10):1720–1728PubMedPubMedCentral

34.

Kamijo Y, Kanda E, Ishibashi Y, Yoshida M (2018) Sarcopenia and frailty in PD: impact on mortality, malnutrition, and inflammation. Perit Dial Int 38(6):447–454PubMed

35.

Kim JK et al (2014) Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr 33(1):64–68PubMed

36.

Kim JK, Kim SG, Oh JE, Lee YK, Noh JW, Kim HJ, Song YR (2019) Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis. Korean J Intern Med 34(3):599–607PubMed

37.

Lin YL, Liou HH, Lai YH, Wang CH, Kuo CH, Chen SY, Hsu BG (2018) Decreased serum fatty acid binding protein 4 concentrations are associated with sarcopenia in chronic hemodialysis patients. Clin Chim Acta 485:113–118PubMed

38.

Mori K et al (2019) Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. BMC Nephrol 20(1):105PubMedPubMedCentral

39.

Ren H, Gong D, Jia F, Xu B, Liu Z (2016) Sarcopenia in patients undergoing maintenance hemodialysis: incidence rate, risk factors and its effect on survival risk. Ren Fail 38(3):364–371PubMed

40.

Tabibi H, As’habi A, Najafi I, Hedayati M (2018) Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients. Kidney Res Clin Pract 37(4):404–413PubMedPubMedCentral

41.

Yoowannakul S, Tangvoraphonkchai K, Vongsanim S, Mohamed A, Davenport A (2018) Differences in the prevalence of sarcopenia in haemodialysis patients: the effects of gender and ethnicity. J Hum Nutr Diet 31(5):689–696PubMed

42.

Cheema B et al (2007) Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol 18(5):594–601

43.

Chen JL et al (2010) Effect of intra-dialytic, low-intensity strength training on functional capacity in adult haemodialysis patients: a randomized pilot trial. Nephrol Dial Transplant 25(6):1936–1943PubMedPubMedCentral

44.

Lopes LCC et al (2019) Intradialytic resistance training improves functional capacity and lean mass gain in individuals on hemodialysis: a randomized pilot trial. Arch Phys Med Rehabil 100(11):2151–2158PubMed

45.

Dong ZJ, Zhang HL, Yin LX (2019) Effects of intradialytic resistance exercise on systemic inflammation in maintenance hemodialysis patients with sarcopenia: a randomized controlled trial. Int Urol Nephrol 51(8):1415–1424PubMedPubMedCentral

46.

Kirkman DL, Mullins P, Junglee NA, Kumwenda M, Jibani MM, Macdonald JH (2014) Anabolic exercise in haemodialysis patients: a randomised controlled pilot study. J Cachexia Sarcopenia Muscle 5(3):199–207PubMedPubMedCentral

47.

Song WJ, Sohng KY (2012) Effects of progressive resistance training on body composition, physical fitness and quality of life of patients on hemodialysis. J Korean Acad Nurs 42(7):947–956PubMed

48.

Baggetta R et al (2018) Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. BMC Geriatr 18(1):248PubMedPubMedCentral

49.

Baria F, Kamimura MA, Aoike DT, Ammirati A, Rocha ML, de Mello MT, Cuppari L (2014) Randomized controlled trial to evaluate the impact of aerobic exercise on visceral fat in overweight chronic kidney disease patients. Nephrol Dial Transplant 29(4):857–864PubMed

50.

Bohm C, Stewart K, Onyskie-Marcus J, Esliger D, Kriellaars D, Rigatto C (2014) Effects of intradialytic cycling compared with pedometry on physical function in chronic outpatient hemodialysis: a prospective randomized trial. Nephrol Dial Transplant 29(10):1947–1955PubMed

51.

Koh KP, Fassett RG, Sharman JE, Coombes JS, Williams AD (2010) Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study. Am J Kidney Dis 55(1):88–99PubMed

52.

Koufaki P, Mercer TH, Naish PF (2002) Effects of exercise training on aerobic and functional capacity of end-stage renal disease patients. Clin Physiol Funct Imaging 22(2):115–124PubMed

53.

DePaul V, Moreland J, Eager T, Clase CM (2002) The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. Am J Kidney Dis 40(6):1219–1229PubMed

54.

Howden EJ, Coombes JS, Strand H, Douglas B, Campbell KL, Isbel NM (2015) Exercise training in CKD: efficacy, adherence, and safety. Am J Kidney Dis 65(4):583–591PubMed

55.

Kopple JD, Wang H, Casaburi R, Fournier M, Lewis MI, Taylor W, Storer TW (2007) Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 18(11):2975–2986PubMed

56.

Liu CK et al (2017) The effect of chronic kidney disease on a physical activity intervention: impact on physical function, adherence, and safety. J Clin Nephrol Ren Care. https://doi.org/10.23937/2572-3286.1510021CrossRefPubMedPubMedCentral

57.

Rossi AP, Burris DD, Lucas FL, Crocker GA, Wasserman JC (2014) Effects of a renal rehabilitation exercise program in patients with CKD: a randomized, controlled trial. Clin J Am Soc Nephrol 9(12):2052–2058PubMedPubMedCentral

58.

Segura-Orti E, Johansen KL (2010) Exercise in end-stage renal disease. Semin Dial 23(4):422–430PubMed

59.

van Vilsteren MC, de Greef MH, Huisman RM (2005) The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 20(1):141–146PubMed

60.

Zhou Y, Hellberg M, Hellmark T, Hoglund P, Clyne N (2019) Muscle mass and plasma myostatin after exercise training: a substudy of Renal Exercise (RENEXC)-a randomized controlled trial. Nephrol Dial Transplant 36(1):95–103PubMedCentral

61.

Yurtkuran M, Alp A, Yurtkuran M, Dilek K (2007) A modified yoga-based exercise program in hemodialysis patients: a randomized controlled study. Complement Ther Med 15(3):164–171PubMed

62.

Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS (2004) Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43(4):607–616PubMed

63.

Hristea D et al (2016) Combining intra-dialytic exercise and nutritional supplementation in malnourished older haemodialysis patients: towards better quality of life and autonomy. Nephrology (Carlton) 21(9):785–790

64.

Allman MA, Stewart PM, Tiller DJ, Horvath JS, Duggin GG, Truswell AS (1990) Energy supplementation and the nutritional status of hemodialysis patients. Am J Clin Nutr 51(4):558–562PubMed

65.

Eustace JA, Coresh J, Kutchey C, Te PL, Gimenez LF, Scheel PJ, Walser M (2000) Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 57(6):2527–2538PubMed

66.

Hiroshige K, Sonta T, Suda T, Kanegae K, Ohtani A (2001) Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 16(9):1856–1862PubMed

67.

Zilles M et al (2018) How to prevent renal cachexia? A clinical randomized pilot study testing oral supplemental nutrition in hemodialysis patients with and without human immunodeficiency virus infection. J Ren Nutr 28(1):37–44PubMed

68.

Kittiskulnam P, Chertow GM, Carrero JJ, Delgado C, Kaysen GA, Johansen KL (2017) Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int 92(1):238–247PubMedPubMedCentral

69.

Heiwe S, Jacobson SH (2011) Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 10:CD003236

70.

Gollie JM, Harris-Love MO, Patel SS, Argani S (2018) Chronic kidney disease: considerations for monitoring skeletal muscle health and prescribing resistance exercise. Clin Kidney J 11(6):822–831PubMedPubMedCentral

71.

Castaneda C et al (2001) Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 135(11):965–976PubMed

72.

Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA (2006) Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 17(11):3149–3157PubMed

73.

Johansen KL, Mulligan K, Schambelan M (1999) Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 281(14):1275–1281PubMed

74.

Macdonald JH, Marcora SM, Jibani MM, Kumwenda MJ, Ahmed W, Lemmey AB (2007) Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study. Nephron Clin Pract 106(3):c125–c135PubMed

75.

Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T (2006) Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 17(8):2307–2314PubMed

76.

Supasyndh O et al (2013) Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. Clin J Am Soc Nephrol 8(2):271–279PubMed

77.

Oh Y (2012) The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities. Kidney Res Clin Pract 31(1):26–37PubMedPubMedCentral

78.

Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW (1991) Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 2(6):1130–1135PubMed

79.

Garibotto G et al (1997) Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 99(1):97–105PubMedPubMedCentral

80.

Pupim LB, Flakoll PJ, Yu C, Ikizler TA (2005) Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 82(6):1235–1243PubMed

81.

Kopple JD, Brunori G, Leiserowitz M, Fouque D (2005) Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant 20(5):952–958PubMed

82.

Ikizler TA, Wingard RL, Breyer JA, Schulman G, Parker RA, Hakim RM (1994) Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 46(4):1178–1183PubMed

83.

Ikizler TA, Wingard RL, Flakoll PJ, Schulman G, Parker RA, Hakim RM (1996) Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Kidney Int 50(1):229–234PubMed

84.

Feldt-Rasmussen B et al (2007) Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 18(7):2161–2171PubMed

85.

Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB (2000) Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 53(2):99–107PubMed

86.

Johannsson G, Bengtsson BA, Ahlmen J (1999) Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 33(4):709–717PubMed

87.

Kopple JD et al (2008) OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 3(6):1741–1751PubMedPubMedCentral

88.

Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007) Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146(2):104–115PubMed

89.

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20(9):2075–2084PubMedPubMedCentral

90.

Stein A et al (1997) Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52(4):1089–1095PubMed

91.

Androga L, Sharma D, Amodu A, Abramowitz MK (2017) Sarcopenia, obesity, and mortality in US adults with and without chronic kidney disease. Kidney Int Rep 2(2):201–211PubMed

92.

Sharma D, Hawkins M, Abramowitz MK (2014) Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States. Clin J Am Soc Nephrol 9(12):2079–2088PubMedPubMedCentral

93.

Malhotra R et al (2017) Sarcopenic obesity definitions by body composition and mortality in the hemodialysis patients. J Ren Nutr 27(2):84–90PubMed

94.

Lamarca F, Carrero JJ, Rodrigues JC, Bigogno FG, Fetter RL, Avesani CM (2014) Prevalence of sarcopenia in elderly maintenance hemodialysis patients: the impact of different diagnostic criteria. J Nutr Health Aging 18(7):710–717PubMed

95.

Foley RN, Wang C, Ishani A, Collins AJ, Murray AM (2007) Kidney function and sarcopenia in the United States general population: NHANES III. Am J Nephrol 27(3):279–286PubMed

96.

Domanski M, Ciechanowski K (2012) Sarcopenia: a major challenge in elderly patients with end-stage renal disease. J Aging Res 2012:754739PubMedPubMedCentral

97.

Fahal IH (2014) Uraemic sarcopenia: aetiology and implications. Nephrol Dial Transplant 29(9):1655–1665PubMed

98.

Avin KG, Moorthi RN (2015) Bone is not alone: the effects of skeletal muscle dysfunction in chronic kidney disease. Curr Osteoporos Rep 13(3):173–179PubMedPubMedCentral

99.

Souza VA, Oliveira D, Mansur HN, Fernandes NM, Bastos MG (2015) Sarcopenia in chronic kidney disease. J Bras Nefrol 37(1):98–105PubMed

100.

Wang XH, Mitch WE (2014) Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 10(9):504–516PubMedPubMedCentral

101.

Bae EJ, Park NJ, Sohn HS, Kim YH (2019) Handgrip strength and all-cause mortality in middle-aged and older Koreans. Int J Environ Res Public Health 16(5):740PubMedCentral

102.

Vogt BP, Borges MCC, Goés CR, Caramori JCT (2016) Handgrip strength is an independent predictor of all-cause mortality in maintenance dialysis patients. Clin Nutr 35(6):1429–1433PubMed

103.

Hwang SH, Lee DH, Min J, Jeon JY (2019) Handgrip strength as a predictor of all-cause mortality in patients with chronic kidney disease undergoing dialysis: a meta-analysis of prospective cohort studies. J Ren Nutr 29(6):471–479PubMed

104.

Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635PubMed

105.

Cozlea DL, Farcas DM, Nagy A, Keresztesi AA, Tifrea R, Cozlea L, Carașca E (2013) The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J 39(4):225–231PubMedPubMedCentral

106.

Lai S et al (2019) Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy. Nutrition 62:108–114PubMed

107.

Hanatani S et al (2018) Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease. Int J Cardiol 268:216–221PubMed

108.

Wang AY et al (2010) Handgrip strength, but not other nutrition parameters, predicts circulatory congestion in peritoneal dialysis patients. Nephrol Dial Transplant 25(10):3372–3379PubMed

109.

Jamal SA, Leiter RE, Jassal V, Hamilton CJ, Bauer DC (2006) Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos Int 17(9):1390–1397PubMed

110.

Cook WL, Tomlinson G, Donaldson M, Markowitz SN, Naglie G, Sobolev B, Jassal SV (2006) Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol 1(6):1197–1204PubMed

111.

Stenvinkel P, Carrero JJ, von Walden F, Ikizler TA, Nader GA (2016) Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol Dial Transplant 31(7):1070–1077PubMed

112.

Chan D, Cheema BS (2016) Progressive resistance training in end-stage renal disease: systematic review. Am J Nephrol 44(1):32–45PubMed

113.

Barcellos FC, Santos IS, Umpierre D, Bohlke M, Hallal PC (2015) Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 8(6):753–765PubMedPubMedCentral

114.

Vanden Wyngaert K et al (2018) The effects of aerobic exercise on eGFR, blood pressure and VO2peak in patients with chronic kidney disease stages 3–4: a systematic review and meta-analysis. PLoS ONE 13(9):e0203662PubMedPubMedCentral

115.

Hernandez HJ, Obamwonyi G, Harris-Love MO (2018) Physical therapy considerations for chronic kidney disease and secondary Sarcopenia. J Funct Morphol Kinesiol 3(1):5PubMed

116.

Hirai K, Ookawara S, Morishita Y (2016) Sarcopenia and physical inactivity in patients with chronic kidney disease. Nephrourol Mon 8(3):e37443PubMedPubMedCentral

117.

Ikizler TA et al (2013) Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int 84(6):1096–1107PubMed

118.

Chen SC, Chung WS, Wu PY, Huang JC, Chiu YW, Chang JM, Chen HC (2019) Associations among Geriatric Nutrition Risk Index, bone mineral density, body composition and handgrip strength in patients receiving hemodialysis. Nutrition 65:6–12PubMed

119.

Bhasin S et al (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2(3):146–159PubMedPubMedCentral

Title: Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment
Authors: Varvara Chatzipetrou
Marie-Josée Bégin
Mélany Hars
Andrea Trombetti
Publication date: 01-01-2022
Publisher: Springer US
Keywords: Sarcopenia
Chronic Kidney Disease
Published in: Calcified Tissue International / Issue 1/2022
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-021-00898-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Degenerations in Global Morphometry of Cancellous Bone in Rheumatoid Arthritis, Osteoarthritis and Osteoporosis of Femoral Heads are Similar but More Severe than in Ageing Controls

Vascular Complications in Individuals with Type 2 Diabetes Mellitus Additionally Increase the Risk of Femoral Neck Fractures Due to Deteriorated Trabecular Microarchitecture

Fibroblast Growth Factor 2 High Molecular Weight Isoforms in Dentoalveolar Mineralization

Neuregulin 4 Attenuates Osteoarthritis Progression by Inhibiting Inflammation and Apoptosis of Chondrocytes in Mice

Authors’ Response to Letter from Professor Birkedal

The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials